therapeutic_5

Bispecific antibodies target two antigens at once. Biointron explores their formats, advantages, and therapeutic potential across cancer, immunology, and emerging indications.

Antibody combination therapies involve the use of two or more antibodies together as a treatment strategy to enhance the therapeutic effect against diseases, such as cancer or infectious diseases. This approach aims to target different epitopes or antigens simultaneously, increasing the efficacy of the treatment by overcoming resistance mechanisms, reducing the likelihood of disease escape, and providing a broader range of action.

Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow, which can cause bone damage, anemia, kidney dysfunction, and weakened immunity. Despite being incurable, advances in antibody therapies have shown significant progress in the management of the disease, highlighting the ongoing efforts in the development of more effective treatments.

VHH antibodies offer stability, small size, and unique binding advantages. Biointron highlights their history, applications, and growing role in research and therapeutics.

Entering into the new year, the popularity of antibody-drug conjugates (ADCs) in the biopharma industry shows no signs of slowing down. In 2023, there were a record number of licensing partnerships in the ADC space, particularly Merck’s $22 billion deal with Daiichi Sankyo, Inc.

Biointron delivers advanced bispecific antibody production with over 260 proven formats, offering rapid expression, scalable solutions, and trusted CRO expertise for therapeutic development.

Combination antibody therapies enhance efficacy by targeting multiple pathways. Biointron showcases synergistic strategies that improve outcomes in cancer and infectious diseases.

Monoclonal antibodies fight antimicrobial resistance by targeting pathogens and complementing antibiotics. Learn how they expand the arsenal against AMR threats.

Cell signaling maps how life communicates. Explore pathways, cross-talk, and the antibody tools that reveal mechanisms behind immunity, cancer, and therapy.

Allotypes represent genetic variation in antibodies. See why they influence immunogenicity, patient response, and global development strategies for safe biologics.

Monoclonal antibodies offer precision and reproducibility—but at a cost. Compare benefits and drawbacks to understand when they are the right tool for your project.

The top FDA antibody approvals of 2023 at a glance: targets, mechanisms, and clinical impact, plus trends that guide smarter project choices in the year ahead.

Compare delivery options for antibody‑based therapies—conjugates, nanoparticles, liposomes, and long‑acting platforms—to improve exposure, precision, and patient safety.

Review the most influential FDA‑approved antibody drugs from 1980–2022, the breakthroughs behind them, and the lessons shaping smarter discovery and development today.

Research into treatments for Alzheimer's disease (AD) has reached impressive milestones this year.